Reviewed by Usama Ali, MPharm (GPhC: 2224726). April 2026.
The combined pill carries a small increased risk of blood clots: around 5 to 7 per 10,000 users per year, compared to 2 per 10,000 in non-users. The mini pill does not increase blood clot risk at all.
About 2 in every 10,000 women who do not use hormonal contraception develop a blood clot per year. Among women taking a combined pill with levonorgestrel (such as Microgynon), that rises to 5 to 7 per 10,000. Among those taking pills with desogestrel, gestodene, or drospirenone, around 9 to 12 per 10,000.
| Pill type | Approximate VTE risk per 10,000/year |
|---|---|
| No hormonal contraception | About 2 |
| Combined pill with levonorgestrel | 5 to 7 |
| Combined pill with desogestrel/gestodene | 9 to 12 |
| Combined pill with drospirenone | 9 to 12 |
| Mini pill (any type) | No increased risk |
| Pregnancy | About 29 |
Risk factors include: family history of blood clots, being over 35 and smoking, BMI above 35, recent surgery or immobility, or a personal history of clots. Your pharmacist checks these before prescribing the combined pill.
Seek urgent help for: painful swelling in one leg, sudden chest pain or difficulty breathing, a sudden severe headache, or sudden vision changes. Call 999 or go to A&E.
The mini pill does not contain oestrogen and does not increase blood clot risk. It is a suitable alternative if clot risk is a concern.
Every consultation includes screening for UKMEC category 3 and 4 conditions. If the combined pill is not suitable, your pharmacist will recommend the mini pill instead.
The risk of a blood clot during pregnancy is around 29 per 10,000. The risk in the first 6 weeks after birth is 300 to 400 per 10,000. The combined pill carries a much smaller risk than pregnancy itself.